• Progress in Targeted Therapy for Lung Cancer: New Data

    10 days ago - By Medscape

    Dr Mark Kris explains why he is even more hopeful when it comes to targeted therapy for lung cancer after seeing several trial results presented during this year's virtual ASCO meeting.
    Medscape Oncology
    Read more ...

     

  • Should ADAURA Trial Results Change Practice in NSCLC?

    10 days ago - By Medscape

    Dr Mark Kris says yes and explains why he thinks 3-year treatment with osimertinib should become the new standard of care for patients with EGFR mutation-positive NSCLC.
    Medscape Oncology
    Read more ...